<DOC>
	<DOCNO>NCT02603146</DOCNO>
	<brief_summary>The purpose study determine hydroxychloroquine ( HCQ ) safe effective prevention future onset rheumatoid arthritis ( RA ) individual elevation autoantibody , anti-cyclic citrullinated peptide ( anti-CCP ) . The following recruitment strategy employ towards identify healthy subject elevate anti-cyclic citrullinated peptide 3 ( anti-CCP3 ) level : -Pre-screening : - first degree relative patient RA ; - subject health-fairs ; - identification subject elevate anti-CCP3 level absence inflammatory arthritis rheumatology clinic .</brief_summary>
	<brief_title>Strategy Prevent Onset Clinically-Apparent Rheumatoid Arthritis</brief_title>
	<detailed_description>Rheumatoid arthritis ( RA ) affect estimate 1 % population . RA disease immune system attack joint , lead joint inflammation damage felt someone RA joint pain , stiffness swelling . Recent study show marker blood call 'autoantibodies ' precede onset joint symptom RA . Antibodies commonly make blood fight infection . Sometimes , antibody attack one 's body . These call autoantibody . Certain autoantibody specific certain disease . The autoantibody know anti-CCP specific RA predict development RA future , especially level anti-CCP high . The investigator study believe individual elevation anti-CCP great 2 time normal value approximately 50 % chance develop RA within 3 year . Hydroxychloroquine ( HCQ ) already use successfully safely treatment malaria , lupus RA . The objective study determine whether treatment HCQ individual elevation anti-CCP without joint inflammation may help prevent future onset RA . This involve 12-month course HCQ prevention development clinically apparent RA 36 month individual high-risk future RA due high titer elevation anti-CCP3 . This study recruit individual without history clinical finding inflammatory arthritis . Eligible subject randomize 1:1 ratio HCQ versus HCQ placebo .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>Subjects meet follow criterion eligible enrollment study : Able willing give write informed consent comply requirement study ; Age ≥18 yearsold Screening Visit ; Elevation autoantibody anticyclic citrullinated peptide ( antiCCP ) define result antiCCP ≥40 unit , Screening . Subjects meet follow criterion ineligible participate study : Evidence significant retinal disease , opinion examiner , would make identification potential future retinal toxicity hydroxychloroquine difficult evaluate ; A medical history inflammatory arthritis ( IA ) type and/or rheumatic disease immunologic disease ( ) may associate IA . These disease include limited : RA ; systemic lupus erythematosus ( SLE ) ; seronegative spondyloarthropathies ; inflammatory bowel disease ; Sjögren 's syndrome ; polymyalgia rheumatic ; vasculitis . Subjects crystalline arthropathy need exclude . Prior current systemic treatment disease modify antirheumatic agent , immunomodulatory agent , glucocorticoid IA , rheumatic disease , immunologic disease ; Minocycline systemic corticosteroid use nonIA condition take 12 month prior Screening Visit ; A history chronic condition , opinion investigator , highly likely require therapy systemic corticosteroid ( oral intravenous ) within study period , include limit severe asthma severe crystalline arthropathy ; Women pregnant , breastfeed desire become pregnant and/or breast feed within duration 12month treatment phase study ; Women childbearing potential use agree use adequate birth control measure ( example , total abstinence , oral contraceptive , intrauterine device , barrier method spermicide , surgical sterilization , DepoProvera , hormonal implant ) treatment phase study ; A medical history : congestive heart failure functional status New York Heart Association ( NYHA ) Class III high Screening Visit ; cardiomyopathy significant cardiac conduction disorder ; cirrhosis ; psoriasis ( due potential increase risk flare skin disease ) ; porphyria ; chronic infection include , limited , human immunodeficiency virus ( HIV ) , hepatitis B ( HBV ) , hepatitis C ( HCV ) Screening Visit ; malignancy within last 5 year , except treat basal squamous cell carcinoma , treat cervical dysplasia , treat situ cervical cancer Grade I ; alcohol substance abuse within 1 year treatment randomization ; An ideal actual body weight ≤ 24.4 kg ( e.g. , ≤53 lb ) Screening Visit ; Any follow laboratory abnormality Screening Visit : Serum Creatinine Clearance &lt; 50ml/min ( calculate CockcroftGault formula : Creatinine clearance ( CrCl ) = ( 140age ) X ( Weight kg ) X ( 0.85 female ) / ( 72 X Creatinine ) ) ; Alanine Aminotransferase ( ALT ) &gt; 2 time upper limit normal ( ULN ) ; Total white blood count ( WBC ) &lt; 3.0 x 10^9/L ; Platelet count ≤ 150 x10^9/L ; Hemoglobin &lt; 11.5g/dL ; Absolute Neutrophil Count ( ANC ) &lt; 2.0 x 10^9/L ; Model EndStage Liver Disease ( MELD ) score ≥10 ; Hepatitis C antibody positivity ; Hepatitis B surface antigen positivity ; That , opinion study physician , good study candidate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>RA prevention</keyword>
	<keyword>hydroxychloroquine ( HCQ )</keyword>
	<keyword>anti-CCP</keyword>
</DOC>